ESR1 and non-small cell lung carcinoma: Furthermore, combinatorial administration of letrozole with PD-1/PD-L1 blockade agents demonstrates synergistic efficacy, offering a promising strategy for optimizing immunotherapy outcomes, especially in 17-β-estradiol/ERα high female NSCLC patients (64).